insights_auto
Why is KYNB up 8.87%?
Dive Deeperchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
$5.28
arrow_upward
+8.87%(+0.43) 1D
Oct 19, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
$5.08
High
$5.29
Low
$4.98
Mkt. cap
21.38M
Avg. vol.
26.16K
Volume
0.00
P/E ratio
0.12
52-wk high
$9.70
52-wk low
$4.85
EPS
$45.30
Beta
1.05
Shares outstanding
4.05M
No. of employees
34
Open
$5.08
High
$5.29
Low
$4.98
Mkt. cap
21.38M
Avg. vol.
26.16K
Volume
0.00
P/E ratio
0.12
52-wk high
$9.70
52-wk low
$4.85
EPS
$45.30
Beta
1.05
Shares outstanding
4.05M
No. of employees
34
News stories
From web sources and news partners
ad-hoc-news.de
·
2 days ago
Kyntra Bio stock fell to USD 4.85 on October 16, down 9.5 percent
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
FoundedJan 1, 1993
HeadquartersSan Francisco, California, United States
SectorBiotechnology
Websitekyntrabio.com